Digital solutions can fill many critical gaps in healthcare. Especially in terms of support for cancer treatment, it can provide tremendous relief for both patients and physicians. Relying on digital therapy, Berlin-based healthcare company Fosanis has raised more than 10m euros in funding to improve its platform.Mika.

Founded in 2017 by Dr Gandolf Finke and others Jan Simon Raue, the digital health company Fosanis aims to enable people affected by cancer. The company’s AI platform for cancer patients, called Mika, helps people with cancer during their illness and treatment. Mika combines AI-driven observation and coaching, including scientifically tested methods and techniques for managing therapy. One of its main features is the daily examination or the so-called electronic patient report (ePRO). This allows continuous monitoring of distress levels and symptoms.

The new funding will allow the startup to enter the UK health ecosystem in 2022. It is also seeking partnerships with international cancer research centers to conduct further research into the medical impact of AI-driven personalization in digital interventions. The Serie A round was led by a Swiss company Debiopharm Innovation Fund with participation from Ship2B Venturesventure capital firm Capital pitcher and an existing shareholder Ananda Impact Ventures.

Fosanis and Mika co-founder and managing director Dr. Jan Simon Raue said: “Cancer knows no boundaries. Helping people affected by cancer is also not a must. We developed Mika to bring back some of the control when guidance and support is most needed: from diagnosis throughout the therapeutic process. Mika provides personalized and comprehensive support for cancer therapy, combining the latest insights into cancer research with 24/7 hands-on help wrapped in an easy-to-use and engaging digital tool.

Fosanis and Mika co-founder and managing director Dr. Gandolf Finke added: “The importance of digital health, and digital therapy in particular, is growing worldwide. This round of funding marks an important milestone in our company’s history, allowing us to scale our oncology DTx platform and position our offerings internationally. ”

Tanya Dow, CEO, Debiopharm Innovation Fund concluded: “Mika promotes patient empowerment and enables those affected to cope with their illness and therapy, regardless of time and location. For this reason, we not only consider ourselves ordinary investors, but also support the company in strategy and implementation. “

Previous articleA civil scientific study found a huge amount of microplastics in Catalonia’s bathing areas
Next articleIntel Vision 2022: All updates and live announcements from Dallas, Texas